Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $136.0 million.
- Jazz Pharmaceuticals' Net Cash Flow fell 8417.4% to $136.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$896.3 million, marking a year-over-year decrease of 20184.72%. This contributed to the annual value of $908.2 million for FY2024, which is 4562.16% up from last year.
- Jazz Pharmaceuticals' Net Cash Flow amounted to $136.0 million in Q3 2025, which was down 8417.4% from -$676.7 million recorded in Q2 2025.
- In the past 5 years, Jazz Pharmaceuticals' Net Cash Flow registered a high of $1.0 billion during Q1 2021, and its lowest value of -$1.2 billion during Q2 2021.
- Over the past 5 years, Jazz Pharmaceuticals' median Net Cash Flow value was $54.4 million (recorded in 2023), while the average stood at $14.3 million.
- Over the last 5 years, Jazz Pharmaceuticals' Net Cash Flow had its largest YoY gain of 149556.64% in 2021, and its largest YoY loss of 153839.29% in 2021.
- Quarter analysis of 5 years shows Jazz Pharmaceuticals' Net Cash Flow stood at -$78.9 million in 2021, then skyrocketed by 147.11% to $37.2 million in 2022, then soared by 353.98% to $168.8 million in 2023, then increased by 16.7% to $197.0 million in 2024, then plummeted by 30.98% to $136.0 million in 2025.
- Its Net Cash Flow stands at $136.0 million for Q3 2025, versus -$676.7 million for Q2 2025 and -$552.6 million for Q1 2025.